Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥487.00 - ¥764.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥5.00B

Enterprise Value¥2.22B

Total Cash (Recent Filing)¥3.53B

Total Debt (Recent Filing)¥1.24B

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Aug 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-89.44

Shares Outstanding10,092,100

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Recent Revenue ReboundA >250% revenue rebound in 2025 indicates renewed commercial traction and demand for Cyfuse’s products and services. Sustained top-line recovery expands the company’s ability to scale operations, supports future margin improvement, and reduces execution risk if growth persists over the next several quarters.

Proprietary Scaffold‑free 3D PlatformThe company’s unique scaffold‑free 3D cell assembly technology represents a durable competitive asset in regenerative medicine. It creates high switching costs for specialized workflows, underpins product, services, and collaboration revenue streams, and supports long‑term differentiation in a niche B2B market.

Manageable Leverage & Equity BaseModerate leverage and a substantial equity base provide balance sheet capacity to fund R&D and operations in the near term. With debt-to-equity under 0.5, the company has financial flexibility to raise or restructure capital without immediate solvency pressure, aiding durability while scaling.

Bears Say

Deep Persistent UnprofitabilityExtremely negative margins reflect a cost structure that is not currently scalable: despite revenue recovery, operating losses dwarf sales. Persistent unprofitability erodes equity over time, forces reliance on external funding, and raises the risk that the business cannot achieve self-sustaining operations without structural changes.

Negative Operating And Free Cash FlowConsistent negative OCF and FCF mean the company cannot internally finance growth or R&D. Ongoing cash burn necessitates repeat capital raises or debt, increasing dilution and refinancing risk. This weak cash generation is a structural constraint on executing medium‑term strategic plans.

Rising Debt Vs Prior YearDebt growth while the company remains unprofitable increases leverage risk and interest burden. Higher borrowings reduce financial flexibility, raise refinancing risk if markets tighten, and can constrain investment in commercialization or R&D unless profitability and cash flow meaningfully improve.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥487.00 and its highest was ¥764.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.00B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Aug 14, 2026 which is in 14 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on May 15, 2026. The company reported -¥22.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.56.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,092,100 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥22.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.622%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.